Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CU06-1004

Phase 2Small molecule

CCuracle Co., Ltd.

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Macular EdemaNot yet recruiting

Macular EdemaPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Macular Edema

NCT07459829

Clinical

Trials by Indication[1]

Macular Edema1 trial

Study of CU06-1004 in Patients With Daibetic Macular Edema

Not yet recruiting·CCuracle Co., Ltd.·Phase 2·NCT07459829·156 enrolled

Diabetic Macular Edema1 trial

The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)

Completed·CCuracle Co., Ltd.·Phase 2·NCT05573100·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CU06-1004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CU06-1004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CU06-1004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Curacle Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCuracle Co., Ltd.

Related News